"Safety and Effectiveness of the Selegiline Patch for Decreased Mental Function in HIV Patients"

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

Not specified

Study Completion Date

December 31, 2005

Conditions
Cognition DisordersHIV Infections
Interventions
DRUG

Selegiline hydrochloride

Trial Locations (15)

10003

Beth Israel Med. Ctr., ACTU, New York

10032

Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York

14642

Univ. of Rochester ACTG CRS, Rochester

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

21287

Johns Hopkins Adult AIDS CRS, Baltimore

27514

Unc Aids Crs, Chapel Hill

60611

Northwestern University CRS, Chicago

60612

Cook County Hosp. CORE Ctr., Chicago

90095

UCLA CARE Center CRS, Los Angeles

92103

Ucsd, Avrc Crs, San Diego

96816

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

98104

University of Washington AIDS CRS, Seattle

02114

Massachusetts General Hospital ACTG CRS, Boston

Unknown

Washington U CRS, St Louis

02906

The Miriam Hosp. ACTG CRS, Providence

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Neurologic AIDS Research Consortium (NARC)

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00013585 - "Safety and Effectiveness of the Selegiline Patch for Decreased Mental Function in HIV Patients" | Biotech Hunter | Biotech Hunter